WO2002019213A3 - Procede de traitement de la migraine - Google Patents

Procede de traitement de la migraine Download PDF

Info

Publication number
WO2002019213A3
WO2002019213A3 PCT/US2001/026740 US0126740W WO0219213A3 WO 2002019213 A3 WO2002019213 A3 WO 2002019213A3 US 0126740 W US0126740 W US 0126740W WO 0219213 A3 WO0219213 A3 WO 0219213A3
Authority
WO
WIPO (PCT)
Prior art keywords
migraine
treatment
pde5 inhibitors
pde5 inhibitor
pde5
Prior art date
Application number
PCT/US2001/026740
Other languages
English (en)
Other versions
WO2002019213A2 (fr
Inventor
Hartmut Porst
Original Assignee
Lilly Icos Llc
Hartmut Porst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Icos Llc, Hartmut Porst filed Critical Lilly Icos Llc
Priority to EP01966306A priority Critical patent/EP1313478A2/fr
Priority to JP2002523251A priority patent/JP2004507514A/ja
Priority to MXPA03001717A priority patent/MXPA03001717A/es
Priority to AU2001286832A priority patent/AU2001286832A1/en
Priority to BR0113644-5A priority patent/BR0113644A/pt
Priority to CA002419623A priority patent/CA2419623A1/fr
Publication of WO2002019213A2 publication Critical patent/WO2002019213A2/fr
Publication of WO2002019213A3 publication Critical patent/WO2002019213A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne un procédé de traitement de la migraine au moyen d'un inhibiteur PDE5, seul ou en combinaison avec un second inhibiteur PDE5 et/ou d'autres agents antimigraineux.
PCT/US2001/026740 2000-08-30 2001-08-27 Procede de traitement de la migraine WO2002019213A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP01966306A EP1313478A2 (fr) 2000-08-30 2001-08-27 Traitement de la migraine par des inhibiteurs de pde5
JP2002523251A JP2004507514A (ja) 2000-08-30 2001-08-27 片頭痛の治療法
MXPA03001717A MXPA03001717A (es) 2000-08-30 2001-08-27 METODO PARA EL TRATAMIENTO DE LA MIGRAnA.
AU2001286832A AU2001286832A1 (en) 2000-08-30 2001-08-27 Method for treatment of migraine using PDE5 inhibitors
BR0113644-5A BR0113644A (pt) 2000-08-30 2001-08-27 Usos do inibidor de pde5 no tratamento de enxaqueca
CA002419623A CA2419623A1 (fr) 2000-08-30 2001-08-27 Procede de traitement de la migraine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22908300P 2000-08-30 2000-08-30
US60/229,083 2000-08-30

Publications (2)

Publication Number Publication Date
WO2002019213A2 WO2002019213A2 (fr) 2002-03-07
WO2002019213A3 true WO2002019213A3 (fr) 2002-10-17

Family

ID=22859786

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/026740 WO2002019213A2 (fr) 2000-08-30 2001-08-27 Procede de traitement de la migraine

Country Status (8)

Country Link
EP (1) EP1313478A2 (fr)
JP (1) JP2004507514A (fr)
CN (1) CN1471397A (fr)
AU (1) AU2001286832A1 (fr)
BR (1) BR0113644A (fr)
CA (1) CA2419623A1 (fr)
MX (1) MXPA03001717A (fr)
WO (1) WO2002019213A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10135815A1 (de) * 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
GB0219024D0 (en) * 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations
DE10325813B4 (de) 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxe und/oder Therapie bei der portalen Hypertonie
MX2009008582A (es) 2007-02-11 2009-10-30 Map Pharmaceuticals Inc Metodo para la administracion terapeutica de dihidroergotamina para permitir un rapido alivio de la migraña mientras se minimiza el perfil de efectos secundarios.
AU2008230710B2 (en) 2007-03-27 2014-04-10 Omeros Corporation The use of PDE7 inhibitors for the treatment of movement disorders
EP2756756B1 (fr) 2008-04-28 2016-01-06 Zogenix, Inc. Compositions inédites destinées au traitement de la migraine
US20130323288A1 (en) 2010-07-08 2013-12-05 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for bedwetting and method of use thereof
US9415048B2 (en) 2010-07-08 2016-08-16 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US10010514B2 (en) 2010-07-08 2018-07-03 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US9532959B2 (en) 2010-07-08 2017-01-03 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US20130040971A1 (en) * 2011-02-14 2013-02-14 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders
US10105330B2 (en) 2012-01-04 2018-10-23 Wellesley Pharmaceuticals, Llc Extended, delayed and immediate release formulation method of manufacturing and use thereof
US10278925B2 (en) 2012-01-04 2019-05-07 Wellesley Pharmaceuticals, Llc Delayed-release formulations, methods of making and use thereof
AU2012363788B2 (en) 2012-01-04 2017-03-09 Wellesley Pharmaceuticals, Llc Delayed-release formulation for reducing the frequency of urination and method of use thereof
WO2014018222A1 (fr) * 2012-07-27 2014-01-30 Wellesley Pharmaceuticals, Llc Formulation pharmaceutique pour réduire la fréquence de miction et son procédé d'utilisation
AU2013361337A1 (en) 2012-12-21 2015-07-09 Map Pharmaceuticals, Inc. 8'-Hydroxy-Dihydroergotamine compounds and compositions
US10792326B2 (en) 2013-06-28 2020-10-06 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for bedwetting and method of use thereof
JP2017114764A (ja) * 2014-04-25 2017-06-29 武田薬品工業株式会社 片頭痛治療剤
US10105328B2 (en) 2014-06-06 2018-10-23 Wellesley Pharmaceuticals, Llc Composition for reducing frequency of urination, method of making and use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CARTLEDGE J ET AL: "SILDENAFIL", EXPERT OPINION ON PHARMACOTHERAPY, ASHLEY, LONDON,, GB, vol. 1, no. 1, 1999, pages 137 - 147, XP000914226, ISSN: 1465-6566 *
FUSCO B M ET AL: "Nitrogen oxide involvement in migraine and cluster headache: Clinical pharmacological indication for difference in the site of action.", CEPHALALGIA, vol. 20, no. 4, May 2000 (2000-05-01), Headache World 2000;London, England, UK; September 03-07, 2000, pages 402, XP008005068, ISSN: 0333-1024 *
GOLDENBERG M M: "SAFETY AND EFFICACY OF SILDENAFIL CITRATE IN THE TREATMENT OF MALE ERECTILE DYSFUNCTION", CLINICAL THERAPEUTICS, EXCERPTA MEDICA, PRINCETON, NJ, US, vol. 20, no. 6, 1998, pages 1033 - 1048, XP000853855, ISSN: 0149-2918 *

Also Published As

Publication number Publication date
CA2419623A1 (fr) 2002-03-07
CN1471397A (zh) 2004-01-28
EP1313478A2 (fr) 2003-05-28
BR0113644A (pt) 2003-07-29
MXPA03001717A (es) 2003-09-22
AU2001286832A1 (en) 2002-03-13
JP2004507514A (ja) 2004-03-11
WO2002019213A2 (fr) 2002-03-07

Similar Documents

Publication Publication Date Title
WO2002019213A3 (fr) Procede de traitement de la migraine
WO2000040235A3 (fr) Traitement de l'asthme a l'aide d'inhibiteurs de mek
WO2002089791A3 (fr) Traitement de l'acne
WO2004105757A3 (fr) Utilisation des inhibiteurs de la rho kinase dans le traitement de l'anevrisme et de l'hypertrophie cardiaque
AU2001282886A1 (en) Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain
WO2005000213A3 (fr) Methode permettant de traiter des maladies a l'aide d'agent d'inhibition hsp90 combines a des inhibiteurs d'enzymes
AU2003201868A1 (en) Aqueous agent for treating substrate, method for treating substrate and treated substrate
AU2001293745A1 (en) Device and method for the surface treatment of workpieces
AU2002215261A1 (en) Method and arrangement for treatment of fluid
AU2001265164A1 (en) Agent and method for treating metal surfaces
MY138732A (en) Conjugated complement cascade inhibitors
WO2003024386A3 (fr) Utilisation d'inhibiteurs c-kit puissants, selectifs et non toxiques pour le traitement de la cystopathie interstitielle sous-muqueuse
AU2002219002A1 (en) Method and device for treating the surfaces of items
MXPA03004870A (es) Combinacion de agonistas de gaba e inhibidores de sorbitol-deshidrogenasa.
WO2003026643A3 (fr) Methodes et combinaisons therapeutiques utiles pour le traitement du xanthome effectue avec des inhibiteurs d'absorption du sterol
AU2001274181A1 (en) Composition and method for biocide treatment of surfaces
WO2002003978A3 (fr) Combinaison d'inhibiteurs de fbpase et d'agents antidiabetiques utile pour le traitement du diabete
AU2002231836A1 (en) Method for treating and drying of wood
AU2002232400A1 (en) Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis
WO2003004006A8 (fr) Utilisation d'inhibiteurs de materiel c, puissants, selectifs et non toxiques pour traiter l'angiogenese tumorale
WO2005115405A8 (fr) Methodes permettant de traiter ou de prevenir la restenose et d'autres troubles vasculaires proliferants
WO2004071413A3 (fr) Procede et composition pour potentialiser un analgesique opiace
WO2005034997A3 (fr) Utilisation de la photosensibilisation
EP1441708A4 (fr) Compositions et methodes permettant d'augmenter l'observance therapeutique au moyen d'inhibiteurs de l'aldehyde deshydrogenase et traitement de l'alcoolisme
WO2001088530A3 (fr) Procede de selection d'inhibiteurs d'enzymes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001286832

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2419623

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/001717

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2002523251

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001966306

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 018177832

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2001966306

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001966306

Country of ref document: EP